Does the media favor RVMD or VRTX?

In the previous week, Vertex Pharmaceuticals had 35 more articles in the media than Revolution Medicines. MarketBeat recorded 57 mentions for Vertex Pharmaceuticals and 22 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.63 beat Vertex Pharmaceuticals' score of 0.62 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Vertex Pharmaceuticals 23 Very Positive mention(s) 9 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to REGN or RVMD?

In the previous week, Regeneron Pharmaceuticals had 32 more articles in the media than Revolution Medicines. MarketBeat recorded 54 mentions for Regeneron Pharmaceuticals and 22 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.63 beat Regeneron Pharmaceuticals' score of 0.42 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Revolution Medicines 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to ARGX or RVMD?

In the previous week, Revolution Medicines had 11 more articles in the media than argenex. MarketBeat recorded 22 mentions for Revolution Medicines and 11 mentions for argenex. argenex's average media sentiment score of 0.92 beat Revolution Medicines' score of 0.63 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to NTRA or RVMD?

In the previous week, Natera had 16 more articles in the media than Revolution Medicines. MarketBeat recorded 38 mentions for Natera and 22 mentions for Revolution Medicines. Natera's average media sentiment score of 0.65 beat Revolution Medicines' score of 0.63 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 19 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Revolution Medicines 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer RVMD or BIIB?

In the previous week, Biogen had 2 more articles in the media than Revolution Medicines. MarketBeat recorded 24 mentions for Biogen and 22 mentions for Revolution Medicines. Biogen's average media sentiment score of 0.98 beat Revolution Medicines' score of 0.63 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Biogen 14 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Revolution Medicines (RVMD) Competitors

$205.15 +7.34 (+3.71%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$203.82 -1.33 (-0.65%)

As of 08/7/2026 07:56 PM Eastern

Compare

RVMD vs. VRTX, REGN, ARGX, NTRA, and BIIB

Should you buy Revolution Medicines stock or one of its competitors? MarketBeat compares Revolution Medicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Revolution Medicines include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), argenex (ARGX), Natera (NTRA), and Biogen (BIIB). These companies are all part of the "biotechnology" industry.

How does Revolution Medicines compare to Vertex Pharmaceuticals?

Revolution Medicines (NASDAQ:RVMD) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Revolution Medicines presently has a consensus price target of $153.05, indicating a potential downside of 25.39%. Vertex Pharmaceuticals has a consensus price target of $563.50, indicating a potential upside of 13.59%. Given Vertex Pharmaceuticals' higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Vertex Pharmaceuticals had 35 more articles in the media than Revolution Medicines. MarketBeat recorded 57 mentions for Vertex Pharmaceuticals and 22 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.63 beat Vertex Pharmaceuticals' score of 0.62 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	23 Very Positive mention(s)	9 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Vertex Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,797.22	-$1.13B	-$7.07	N/A
Vertex Pharmaceuticals	$12.00B	10.49	$3.95B	$17.18	28.87

Vertex Pharmaceuticals has a net margin of 35.00% compared to Revolution Medicines' net margin of 0.00%. Vertex Pharmaceuticals' return on equity of 23.09% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-102.61%	-70.72%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Regeneron Pharmaceuticals has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.78	$4.50B	$40.46	19.39
Revolution Medicines	$11.58M	3,797.22	-$1.13B	-$7.07	N/A

In the previous week, Regeneron Pharmaceuticals had 32 more articles in the media than Revolution Medicines. MarketBeat recorded 54 mentions for Regeneron Pharmaceuticals and 22 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.63 beat Regeneron Pharmaceuticals' score of 0.42 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Revolution Medicines	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Revolution Medicines' net margin of 0.00%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Revolution Medicines	N/A	-102.61%	-70.72%

Regeneron Pharmaceuticals currently has a consensus price target of $797.75, indicating a potential upside of 1.71%. Revolution Medicines has a consensus price target of $153.05, indicating a potential downside of 25.39%. Given Regeneron Pharmaceuticals' higher probable upside, equities research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.67
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Summary

Regeneron Pharmaceuticals beats Revolution Medicines on 9 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to argenex?

argenex (NASDAQ:ARGX) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

60.3% of argenex shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

argenex has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

In the previous week, Revolution Medicines had 11 more articles in the media than argenex. MarketBeat recorded 22 mentions for Revolution Medicines and 11 mentions for argenex. argenex's average media sentiment score of 0.92 beat Revolution Medicines' score of 0.63 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

argenex currently has a consensus price target of $1,056.89, suggesting a potential upside of 22.18%. Revolution Medicines has a consensus price target of $153.05, suggesting a potential downside of 25.39%. Given argenex's higher possible upside, equities research analysts clearly believe argenex is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

argenex has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.74	$1.29B	$26.04	33.22
Revolution Medicines	$11.58M	3,797.22	-$1.13B	-$7.07	N/A

argenex has a net margin of 32.19% compared to Revolution Medicines' net margin of 0.00%. argenex's return on equity of 43.59% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Revolution Medicines	N/A	-102.61%	-70.72%

Summary

argenex beats Revolution Medicines on 9 of the 15 factors compared between the two stocks.

How does Revolution Medicines compare to Natera?

Natera (NASDAQ:NTRA) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Natera has higher revenue and earnings than Revolution Medicines. Natera is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.00	-$208.16M	-$1.63	N/A
Revolution Medicines	$11.58M	3,797.22	-$1.13B	-$7.07	N/A

Revolution Medicines has a net margin of 0.00% compared to Natera's net margin of -7.11%. Natera's return on equity of -11.82% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.82%	-8.19%
Revolution Medicines	N/A	-102.61%	-70.72%

99.9% of Natera shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 5.1% of Natera shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Natera currently has a consensus price target of $299.65, suggesting a potential downside of 6.97%. Revolution Medicines has a consensus price target of $153.05, suggesting a potential downside of 25.39%. Given Natera's higher possible upside, equities research analysts clearly believe Natera is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	2 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.77
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

In the previous week, Natera had 16 more articles in the media than Revolution Medicines. MarketBeat recorded 38 mentions for Natera and 22 mentions for Revolution Medicines. Natera's average media sentiment score of 0.65 beat Revolution Medicines' score of 0.63 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	19 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Revolution Medicines	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Natera has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

Summary

Natera beats Revolution Medicines on 10 of the 16 factors compared between the two stocks.

How does Revolution Medicines compare to Biogen?

Revolution Medicines (NASDAQ:RVMD) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

In the previous week, Biogen had 2 more articles in the media than Revolution Medicines. MarketBeat recorded 24 mentions for Biogen and 22 mentions for Revolution Medicines. Biogen's average media sentiment score of 0.98 beat Revolution Medicines' score of 0.63 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Biogen	14 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

Revolution Medicines presently has a consensus price target of $153.05, indicating a potential downside of 25.39%. Biogen has a consensus price target of $224.61, indicating a potential upside of 8.02%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Biogen has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,797.22	-$1.13B	-$7.07	N/A
Biogen	$9.89B	3.11	$1.29B	$5.65	36.80

Biogen has a net margin of 8.32% compared to Revolution Medicines' net margin of 0.00%. Biogen's return on equity of 11.18% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-102.61%	-70.72%
Biogen	8.32%	11.18%	6.88%

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Biogen beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

Get Revolution Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVMD vs. The Competition

Export

Metric	Revolution Medicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$43.97B	$3.70B	$7.03B	$13.02B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-23.26	9.02	271.36	25.17
Price / Sales	3,797.22	1,303.67	600.88	88.07
Price / Cash	N/A	102.35	71.81	50.72
Price / Book	24.31	18.10	13.25	6.22
Net Income	-$1.13B	-$13.25M	$3.45B	$342.66M
7 Day Performance	9.40%	6.24%	4.67%	4.41%
1 Month Performance	8.10%	-2.70%	-0.79%	-0.28%
1 Year Performance	486.14%	61.17%	76.94%	22.60%

Revolution Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVMD Revolution Medicines	1.6026 of 5 stars	$205.15 +3.7%	$153.05 -25.4%	+487.0%	$43.97B	$11.58M	N/A	250	Earnings Report Analyst Forecast
VRTX Vertex Pharmaceuticals	4.1497 of 5 stars	$470.72 -1.3%	$559.61 +18.9%	+32.1%	$121.09B	$12.00B	27.92	6,400	Trending News Earnings Report Analyst Forecast
REGN Regeneron Pharmaceuticals	3.352 of 5 stars	$759.24 -0.4%	$797.75 +5.1%	+40.1%	$80.63B	$14.34B	18.77	15,410	Trending News
ARGX argenex	4.5051 of 5 stars	$830.79 -2.7%	$1,056.89 +27.2%	+28.7%	$53.42B	$4.25B	31.90	1,863	Analyst Forecast
NTRA Natera	2.9322 of 5 stars	$270.36 +1.0%	$267.83 -0.9%	+128.3%	$38.35B	$2.50B	N/A	6,140	Trending News Earnings Report Analyst Forecast Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVMD) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revolution Medicines (RVMD) Competitors

RVMD vs. VRTX, REGN, ARGX, NTRA, and BIIB

How does Revolution Medicines compare to Vertex Pharmaceuticals?

Summary

How does Revolution Medicines compare to Regeneron Pharmaceuticals?

Summary

How does Revolution Medicines compare to argenex?

Summary

How does Revolution Medicines compare to Natera?

Summary

How does Revolution Medicines compare to Biogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Revolution Medicines (RVMD) Competitors

RVMD vs. VRTX, REGN, ARGX, NTRA, and BIIB

How does Revolution Medicines compare to Vertex Pharmaceuticals?

Do analysts recommend RVMD or VRTX?

Does the media favor RVMD or VRTX?

Which has more risk and volatility, RVMD or VRTX?

Which has higher valuation and earnings, RVMD or VRTX?

Is RVMD or VRTX more profitable?

Do institutionals and insiders hold more shares of RVMD or VRTX?

Summary

How does Revolution Medicines compare to Regeneron Pharmaceuticals?

Which has more volatility and risk, REGN or RVMD?

Do institutionals and insiders believe in REGN or RVMD?

Which has preferable valuation & earnings, REGN or RVMD?

Does the media refer more to REGN or RVMD?

Is REGN or RVMD more profitable?

Do analysts rate REGN or RVMD?

Summary

How does Revolution Medicines compare to argenex?

Do institutionals & insiders believe in ARGX or RVMD?

Which has more volatility and risk, ARGX or RVMD?

Does the media refer more to ARGX or RVMD?

Do analysts prefer ARGX or RVMD?

Which has preferable earnings & valuation, ARGX or RVMD?

Is ARGX or RVMD more profitable?

Summary

How does Revolution Medicines compare to Natera?

Which has preferable earnings & valuation, NTRA or RVMD?

Is NTRA or RVMD more profitable?

Do institutionals & insiders believe in NTRA or RVMD?

Do analysts prefer NTRA or RVMD?

Does the media refer more to NTRA or RVMD?

Which has more volatility and risk, NTRA or RVMD?

Summary

How does Revolution Medicines compare to Biogen?

Does the media prefer RVMD or BIIB?

Which has more volatility and risk, RVMD or BIIB?

Do analysts recommend RVMD or BIIB?

Which has higher valuation & earnings, RVMD or BIIB?

Is RVMD or BIIB more profitable?

Do insiders and institutionals believe in RVMD or BIIB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools